Rabab cancer Foundation

‏جمعية رسمية تعمل لنشر الوعي حول مرض السرطان وتحسين مستوى الحياة للمرضى

[Rabab cancer Foundation @rababcancerfou1]

Unlocking a breakthrough: a game-changing gene study reveals the hidden risk factors for uveal melanoma, giving hope to thousands of patients worldwide.

[Rabab cancer Foundation @rababcancerfou1]

Early detection saves lives—see how UK attitudes on cancer screening are changing to protect you better!

[Rabab cancer Foundation @rababcancerfou1]

miR-302 family shrinks tongue cancer tumors—new hope for a deadlier disease.

[Rabab cancer Foundation @rababcancerfou1]

"A breakthrough drug makes radiation 10x deadlier to killer lymphoma—new hope for untreatable cases."

[Rabab cancer Foundation @rababcancerfou1]

FDA approved rusfertide for polycythemia vera. First hepcidin mimetic reduces erythropoiesis by limiting iron availability. Offers a targeted option for patients refractory to phlebotomy or cytoreductives.

[Rabab cancer Foundation @rababcancerfou1]

Perioperative tislelizumab plus chemotherapy improves mPR only in tsMHC-II-positive gastric cancer, not in negative patients. This phase 2 trial validates tsMHC-II as a predictive biomarker for patient selection.

[Rabab cancer Foundation @rababcancerfou1]

On-treatment core needle biopsy after 2-4 cycles of NACT identifies breast cancer patients with 98% chance of axillary pCR if cN0, enabling safe omission of axillary surgery. In cN+ early responders, adding post-treatment MRI raises axillary pCR prediction to 89.6%.

[Rabab cancer Foundation @rababcancerfou1]

CD19 CAR T cells achieved DAS28-CRP remission in 5 of 6 patients with treatment-refractory ACPA-positive RA in a phase 1 trial, with no ICANS and manageable CRS.

[Rabab cancer Foundation @rababcancerfou1]

Brain barriers restrict immune surveillance of CNS parenchyma, directly limiting checkpoint inhibitor, vaccine, and CAR-T efficacy in gliomas. Preclinical evidence suggests targeting barrier-mediated immune exclusion may improve immunotherapy delivery.

[Rabab cancer Foundation @rababcancerfou1]

Ovarian cancer patients are now living longer, thanks to groundbreaking new treatment approaches that are rewriting the rules of survival.

[Rabab cancer Foundation @rababcancerfou1]

Intracranial B7-H3 CAR-T in rGBM phase 1: no DLTs, 86.7% low-grade CRS, 13/15 patients received repeated infusions. Does locoregional delivery overcome the trafficking barrier enough to justify the invasiveness in recurrent GBM? #CARTcell #Glioblastoma #ImmunoOncology

[Rabab cancer Foundation @rababcancerfou1]

Kaposi sarcoma TME differs by HIV status even with controlled viremia. Non-HIV KS shows upregulated adaptive immunity and angiogenesis. HIV-associated KS has lower activated CD4 infiltration. Preclinical.

[Rabab cancer Foundation @rababcancerfou1]

FGD5 loss sensitizes PDAC to 2-DG by shifting metabolism from glycolysis to OXPHOS. FGD5 stabilizes PGK1 by blocking STUB1-mediated ubiquitination. Preclinical.

[Rabab cancer Foundation @rababcancerfou1]

HER2-positive breast cancers resistant to tucatinib show AKAP13-driven suppression of GLI1/ULK1-dependent autophagy. Targeting AKAP13 resensitizes preclinical models to next-generation TKIs and ADCs.

[Rabab cancer Foundation @rababcancerfou1]

Blocking SELP/PSGL1 reprograms M2 macrophages, breaks the lactate-driven feed-forward loop, and sensitizes gastric cancer to anti-PD-1 in preclinical models.

[Rabab cancer Foundation @rababcancerfou1]

Treating metastases as extensions of primary tumors is failing patients. This review maps how clinical metastases evolve, from early vs late dissemination to organ-specific colonization and therapy-driven selection. Preclinical evidence frames the biology.

[Rabab cancer Foundation @rababcancerfou1]

Ultraprocessed food intake linked to higher prostate cancer risk in a large cohort. Does dietary modulation of IGF-1 or chronic inflammation drive this association in hormone-sensitive disease Preclinical only #prostatecancer #ultraprocessedfood #cancerprevention

[Rabab cancer Foundation @rababcancerfou1]

TIM3-targeted delivery turns venetoclax into a dual weapon: overcomes drug resistance and reawakens NK cells against AML blasts in preclinical models.

[Rabab cancer Foundation @rababcancerfou1]

ctDNA outperformed CEA/CA15-3 for predicting recurrence and survival in inflammatory breast cancer in this retrospective analysis. ctDNA dynamics captured relapse earlier and stratified risk more precisely than conventional markers.

[Rabab cancer Foundation @rababcancerfou1]

Local C3 in the tumor microenvironment blocks immunosuppressive myeloid cell infiltration. Could intratumoral complement production be a biomarker for checkpoint inhibitor response in solid tumors Preclinical data. #TumorMicroenvironment #ComplementBiology #CancerImmunotherapy